UNCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UNCY is not a good buy right now for an impatient investor. Despite a clear positive FDA catalyst (NDA acceptance with a June 2026 action date), the stock just sold off hard in the regular session (-10.49%) and is trading right on/just below near-term support (~6.05) with weakening momentum (MACD worsening). The setup is more “wait for stabilization and reclaim of key levels” than “buy immediately.”
Price/Trend: The stock dropped sharply during the regular session (-10.49%) and is only modestly higher post-market (+0.84%) around ~6.02. It’s sitting at a critical area: S1 ~6.054 (price is slightly below/around it), with the next support at S2 ~5.71. Resistance levels above are Pivot ~6.612, then R1 ~7.17. Momentum: MACD histogram is negative (-0.0228) and negatively expanding, signaling bearish momentum increasing. RSI: RSI_6 ~31, near oversold territory (not deeply oversold), which can support a short-term bounce attempt but does not confirm a reversal. Moving Averages: The MA stack is bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure had been constructive; however, the sudden selloff plus weakening MACD implies the short-term trend is damaged and needs confirmation (ideally a reclaim of ~6.61 pivot). Bottom line technically: Near-term is fragile; a bounce is possible from ~6.05/5.71 support, but the current tape is not showing confirmed upside follow-through.
FDA accepted the New Drug Application (NDA) for oxylanthanum carbonate; this is a meaningful regulatory milestone. A defined target action date in late June 2026 creates a clear, event-driven roadmap and can attract speculative interest ahead of the decision.
Hedge fund and insider activity are reported as neutral (no negative signal from notable selling pressure in the provided data).
Strong “sell-the-news” style reaction: the stock fell -10.49% during the regular session despite the positive FDA acceptance headlines, indicating weak immediate demand and/or profit-taking.
Regulatory catalyst timing is months away (June 2026 action date), which reduces urgency for immediate buying if the goal is quick upside.
Extremely high implied volatility signals large downside risk potential alongside upside, and today’s put-heavy volume ratio suggests short-term caution.
Latest reported quarter: 2025/Q3. Revenue was 0 (no operating revenue reported). Net loss improved YoY to about -$6.01M (improvement of ~46.75% YoY), but EPS worsened to -0.33 (down ~28.26% YoY). Overall, this still reads like a pre-commercial biotech profile where the stock is driven more by regulatory events than by operating growth trends.
No analyst rating or price-target change data was provided, so a recent trend in Wall Street ratings/targets cannot be confirmed from the dataset. With the available information, the pro case is event-driven upside from the FDA review path, while the con case is the market’s immediate negative price reaction and the long wait to the June 2026 decision.
